The Latest Breaking News from Omicron

The U.S. Food and Drug Administration (FDA) has announced clearance to Insulet’s (NASDAQ:PODD) Omnipod 5 Automated Insulin Delivery System (Omnipod 5) for individuals aged two years and older with type 1 diabetes (T1D). Insulet shares traded in a range of $260.13 to $266.73 on day volume of 200.86 thousand shares…

Pfizer Inc. and BioNTech SE asked the U.S. to authorize a new COVID-19 booster shot customized against the currently circulating COVID-19 variants as governments race to protect their populations against the ever-mutating virus.

The full version of the Government's variant plan, released under the Official Information Act, shows no specific responses were drawn up for different scenarios.

Pfizer has submitted data on its bivalent COVID-19 booster shot that specifically targets the latest omicron subvariants. If authorized, the company says the shots could be ready as soon as September.

Pfizer has asked U.S. regulators to authorize its combination COVID-19 vaccine that adds protection against the newest omicron relatives

LOS ANGELES — As the latest coronavirus wave fueled by the super-infectious omicron subvariant BA.5 continues to recede, health officials are turning a wary eye to what might come next.

Around one in five vaccinated Britons with Omicron or Delta strain experienced diarrhoea as a symptom

The Omicron sub-variant BA.5 is less likely to make Covid patients immune to the virus

‘Even having had Omicron, we’re not well protected from further infections,’ said Prof Danny Altmann

UK hit by fifth wave of infections earlier this summer driven by new Omicron variants

Fainting and fatigue may signal onset of variant, experts say